The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer.
Junichi Hasegawa
No relevant relationships to disclose
Tsunekazu Mizushima
No relevant relationships to disclose
Ho Min Kim
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Hiroyoshi Takemoto
No relevant relationships to disclose
Hiroshi Tamagawa
No relevant relationships to disclose
Shingo Noura
No relevant relationships to disclose
Masayuki Ohue
No relevant relationships to disclose
Makoto Fujii
No relevant relationships to disclose
Yuichiro Fujie
No relevant relationships to disclose
Hirofumi Ota
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Ichiro Takemasa
No relevant relationships to disclose
Masataka Ikeda
No relevant relationships to disclose
Hirofumi Yamamoto
No relevant relationships to disclose
Mistugu Sekimoto
No relevant relationships to disclose
Riichiro Nezu
No relevant relationships to disclose
Yuichiro Doki
No relevant relationships to disclose
Masaki Mori
No relevant relationships to disclose